KAPA
Kairos Pharma, Ltd.
NYSE MKT: KAPA · HEALTHCARE · BIOTECHNOLOGY
$0.55
-6.44% today
Updated 2026-04-29
Market cap
$12.83M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.30
Dividend yield
—
52W range
$0 – $2
Volume
0.6M
Kairos Pharma, Ltd. (KAPA) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — |
| Cost of revenue | — | $98000.00 | $160000.00 | $160000.00 | $160000.00 | — |
| Gross profit | — | $-98000.00 | $-160000.00 | $-160000.00 | $-160000.00 | — |
| Gross margin | — | — | — | — | — | — |
| R&D | $20000.00 | $183000.00 | $87000.00 | $82000.00 | $414000.00 | $2.13M |
| SG&A | $1.03M | $1.66M | $324000.00 | $1.47M | $1.93M | $3.44M |
| Operating income | $-1.05M | $-1.94M | $-571000.00 | $-1.71M | $-2.34M | $-5.57M |
| Operating margin | — | — | — | — | — | — |
| EBITDA | $-1.05M | $-1.84M | $-411000.00 | $-1.55M | $-1.58M | $-5.29M |
| EBITDA margin | — | — | — | — | — | — |
| EBIT | $-1.05M | $-1.94M | $-571000.00 | $-1.71M | $-1.74M | $-5.45M |
| Interest expense | $5411.00 | $202000.00 | $479000.00 | $98000.00 | $859000.00 | $0.00 |
| Income tax | — | — | — | — | $-2.60M | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 50.0% | 0.0% |
| Net income | $-1.05M | $-2.15M | $-1.05M | $-1.81M | $-2.60M | $-5.45M |
| Net income growth (YoY) | — | -104.0% | +51.0% | -72.6% | -43.7% | -109.3% |
| Profit margin | — | — | — | — | — | — |